SCHEMBL6307060

SCHEMBL6307060

CSc1nc(N)nc(CN2CCN(c3ccccc3F)CC2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.64
MAPT P10636 7/20 0.62
USP2 O75604 5/20 0.62
TDP1 Q9NUW8 3/20 0.62
HTT P42858 1/20 0.62
MAPK1 P28482 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 4/20 0.59
SLC29A2 Q14542 2/20 0.59
SLC29A1 Q99808 2/20 0.59
HSD17B10 Q99714 2/20 0.59
GLA P06280 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
LMNA P02545 4/20 0.57
GAA P10253 1/20 0.55
TSHR P16473 2/20 0.50
POLB P06746 1/20 0.50
GRM2 Q14416 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6308323 0.78 ALDH1A1 (0.45) ALDH1A1MAPTUSP2MAPK1MEN1
SCHEMBL6307171 0.76 GAA (0.50) ALDH1A1HTTMAPK1SMN1; SMN2L3MBTL1
SCHEMBL6307905 0.74 CYBB (0.58) ALDH1A1MAPTUSP2TDP1HTT
SCHEMBL27846989 0.74 SLC29A2 (1.00) ALDH1A1MAPTUSP2TDP1HTT
SCHEMBL6310022 0.74 ALDH1A1 (0.50) ALDH1A1MAPTUSP2TDP1MAPK1
SCHEMBL6310015 0.74 ALDH1A1 (0.50) ALDH1A1MAPTUSP2TDP1MAPK1
SCHEMBL6314302 0.71 HSP90AA1 (0.41) ALDH1A1MAPTUSP2MAPK1SMN1; SMN2
SCHEMBL13568797 0.68 ALDH1A1 (0.71) ALDH1A1TDP1MAPK1SMN1; SMN2KDM4E
SCHEMBL8044642 0.68 KDM4E (0.65) ALDH1A1TDP1SMN1; SMN2KDM4EHSD17B10
SCHEMBL4414889 0.67 LMNA (0.46) ALDH1A1MAPTUSP2TDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919339-B2 ABCA-1 elevating compounds CV THEAPEUTICS, INC. (US) 2005-07-19 US disclosed
EP-1341773-A2 SUBSTITUTED 1,3,5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2003-09-10 EP disclosed
US-20020128266-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2002-09-12 US disclosed
WO-2002046172-A2 SUBSTITUTED 1, 3, 5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128266-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 ALDH1A1 399/4885MAPT 4100/4885USP2 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.